RESUMEN
Myelodysplastic syndromes (MDS) comprise a spectrum of clonal stem cell disorders which are currently defined according to the classification scheme of the revised 2008 WHO classification but which may be further refined in the future. The clinical presentation is often characterized by unexplained isolated or multiple peripheral blood cytopenias resulting in anemia, bleeding events or increased susceptibility to infections. The generally hypercellular, but rarely hypocellular and occasionally fibrotic bone marrow shows dysplastic features in ≥ 10 % of cells of at least one of the hematopoietic lineages. These features and enhanced apoptosis, stem cell senescence and immunologic dysregulation result in ineffective hematopoiesis. Diagnostics in MDS relies on complementary consideration of hematological, morphological and cytogenetic/molecular parameters. Methods include marrow and peripheral blood cytology, cytogenetics, fluorescence in situ hybridization (FISH), trephine bone marrow biopsy examination, immunophenotyping and the evaluation of molecular markers by established and new techniques. Mutations affecting growth factor receptors, cell cycle and apoptosis regulators, intracellular signaling, transcription factors, epigenetic regulation and the splicosome are involved in MDS pathogenesis and progression.
Asunto(s)
Síndromes Mielodisplásicos/genética , Síndromes Mielodisplásicos/patología , Biomarcadores de Tumor/genética , Biopsia con Aguja , Células Sanguíneas/patología , Médula Ósea/patología , Estudios Transversales , Análisis Citogenético/métodos , Análisis Mutacional de ADN/métodos , Células Madre Hematopoyéticas/patología , Humanos , Inmunofenotipificación/métodos , Hibridación Fluorescente in Situ/métodos , Síndromes Mielodisplásicos/clasificación , Síndromes Mielodisplásicos/epidemiología , Pronóstico , Factores de RiesgoAsunto(s)
Aberraciones Cromosómicas , Cromosomas Humanos Par 8/genética , Histiocitosis de Células de Langerhans/diagnóstico , Histiocitosis de Células de Langerhans/genética , Sarcoma Mieloide/diagnóstico , Sarcoma Mieloide/genética , Trisomía/genética , Diagnóstico Diferencial , Femenino , Humanos , Persona de Mediana Edad , PronósticoRESUMEN
Myeloproliferative neoplasms (MPNs) and related chronic disorders constitute a subgroup of myeloid malignancies which are defined according to clinical, morphological and molecular features by the actual World Health Organization classification of tumors of the haematopietic system. Screening procedures for a BCR-ABL fusion gene, JAK2, thrombopoietin receptor and KIT mutations are formally included in the diagnostic approach. Myelodysplastic/MPN overlap syndromes include rare entities such as refractory anemia with ringed sideroblasts characterized by a high proportion of JAK2V617F mutated cases. The paradigm of targeted treatment of chronic myeloid leukemia with imatinib has now been extended to eosinophilia-associated myeloid neoplasms with PDGFRA, PDGFRB or FGFR1 gene mutations. Pegylated interferon-alpha has convincingly been proved to reduce the JAK2 allele burden. JAK2 inhibitor drugs are currently being tested in clinical trials. The development of pathogenesis-targeted diagnostic and therapeutic approaches to the various MPNs will continue in the future.